Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. euroxpand

EuroXpand SIGNED

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroXpand project word cloud

Explore the words cloud of the EuroXpand project. It provides you a very rough idea of what is the project "EuroXpand" about.

industrialised    patients    cellprothera    therapy    model    heart    proof    demonstrated    stempack    efficacy    leader    infarction    socio    operative    patented    death    outcomes    successful    total    recovery    worldwide    reference    direct    treatments    outstanding    stem    myocardial    2008    prevention    pilot    safety    invasive    health    competitors    position    least    post    demonstration    nor    issue    reinsertion    83    founded    decreasing    indicated    function    assets    jobs    life    euroxpand    context    profile    reg    founder    automate    35    kit    thousands    combined    acute    pr    affordable    business    centres    creation    stemxpand    cancer    turnover    hence    worked    2021    cell    public    thanks    expansion    global    countries    expectancy    ami    fail    limiting    2022    euros    75    first    possession    surgical    treatment    indirect    eacute    characterised    cardiac    billion    millions    clinical    prevent    innovative    discoveries    professional    cells    hf    unlike    burdensome    excellent   

Project "EuroXpand" data sheet

The following table provides information about the project.

Coordinator		 CELLPROTHERA 

Organization address
address: 12 RUE DU PARC
city: MULHOUSE
postcode: 68100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 5˙000˙000 €
 EC max contribution 5˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLPROTHERA FR (MULHOUSE) coordinator 5˙000˙000.00

Map

 Project objective

Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 1,9 billion euros in 2021, associated to the creation of at least 40 direct jobs by 2022 and several thousands of indirect jobs, particularly in Cell Therapy Centres.

 Deliverables

List of deliverables.
Communication material (brochures, web…) Documents, reports 2020-02-12 17:33:26
Press Release - Project kick-off Documents, reports 2020-02-12 17:33:28

Take a look to the deliverables list in detail:  detailed list of EuroXpand deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EUROXPAND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EUROXPAND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More